BioSyent Schedules Q2 and H1 2017 Earnings Release for August 16, 2017
August 08 2017 - 8:00AM
BioSyent Inc. (“BioSyent”) (TSX Venture:RX) will be reporting its
financial results for the three and six months ended June 30, 2017
on Wednesday, August 16, 2017 at 8:00am (ET). A presentation
on the Company’s second quarter and first half 2017 results by Mr.
René Goehrum, BioSyent President and CEO, will also be available on
the Company’s website on the date of release.
About BioSyent Inc.
Listed on the TSX Venture Exchange under the
trading symbol “RX”, BioSyent is a profitable growth-oriented
specialty pharmaceutical company focused on in-licensing or
acquiring innovative pharmaceutical and other healthcare products
that have been successfully developed, are safe and effective, and
have a proven track record of improving the lives of
patients. BioSyent supports the healthcare professionals that
treat these patients by marketing its products through its
community, hospital and international business units.
As of the date of this press release, the
Company has 14,476,353 shares issued and outstanding.
For a direct market quote (15 minutes delay) for
the TSX Venture Exchange and other Company financial information
please visit www.tmxmoney.com.
For further information please contact:
Mr. René C. Goehrum
President and CEO
BioSyent Inc.
Tel: (905) 206-0013
E-Mail: investors@biosyent.com
Web: www.biosyent.com
Biosyent (TSXV:RX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Biosyent (TSXV:RX)
Historical Stock Chart
From Sep 2023 to Sep 2024